Cargando…

Pharmacological antagonism of the incretin system protects against diet-induced obesity

OBJECTIVE: Glucose-dependent insulinotropic polypeptide is an intestinally derived hormone that is essential for normal metabolic regulation. Loss of the GIP receptor (GIPR) through genetic elimination or pharmacological antagonism reduces body weight and adiposity in the context of nutrient excess....

Descripción completa

Detalles Bibliográficos
Autores principales:	Svendsen, Berit, Capozzi, Megan E., Nui, Jingjing, Hannou, Sarah A., Finan, Brian, Naylor, Jacqueline, Ravn, Peter, D'Alessio, David A., Campbell, Jonathan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939028/ https://www.ncbi.nlm.nih.gov/pubmed/32029229 http://dx.doi.org/10.1016/j.molmet.2019.11.018

Ejemplares similares

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018)

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
por: Finan, Brian, et al.
Publicado: (2020)

Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
por: Salehi, Marzieh, et al.
Publicado: (2012)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

Molecular Pharmacology of the Incretin Receptors
por: Al-Sabah, Suleiman
Publicado: (2016)

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
por: El, Kimberley, et al.
Publicado: (2023)

Temporal plasticity of insulin and incretin secretion and insulin sensitivity following sleeve gastrectomy contribute to sustained improvements in glucose control
por: Douros, Jonathan D., et al.
Publicado: (2019)

Fucoidan antagonizes diet-induced obesity and inflammation in mice
por: Wang, Lei, et al.
Publicado: (2021)

Editorial: Incretin agonists in the treatment of obesity
por: Sun, Xiaodong, et al.
Publicado: (2023)

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
por: Tan, Qiming, et al.
Publicado: (2022)

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
por: Campbell, Jonathan E.
Publicado: (2020)

Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
por: Gilroy, C. A., et al.
Publicado: (2020)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Incretin Concepts
por: Bloomgarden, Zachary T.
Publicado: (2010)

Inflammation and incretins
por: Hatwal, Amitabh
Publicado: (2012)

Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
por: Michałowska, Joanna, et al.
Publicado: (2021)

Pleiotropic effects of incretins
por: Gupta, Vishal
Publicado: (2012)

Incretin-based therapies
por: Stonehouse, Anthony H, et al.
Publicado: (2012)

β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation
por: Panaro, Brandon L., et al.
Publicado: (2017)

β-Cell Function, Incretin Effect, and Incretin Hormones in Obese Youth Along the Span of Glucose Tolerance From Normal to Prediabetes to Type 2 Diabetes
por: Michaliszyn, Sara F., et al.
Publicado: (2014)

Pancreatitis Associated With Incretin-Based Therapies
por: Iyer, Shridhar N., et al.
Publicado: (2013)

Incretin responses to oral glucose load in Japanese non-obese healthy subjects
por: Nagai, Etsuko, et al.
Publicado: (2011)

Targeted intestinal delivery of incretin secretagogues—towards new diabetes and obesity therapies
por: Gribble, Fiona M., et al.
Publicado: (2018)

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
por: Marrano, Nicola, et al.
Publicado: (2021)

Understanding the Cardiovascular Effects of Incretin
por: Yoon, Ji Sung, et al.
Publicado: (2011)

Incretin hormones as immunomodulators of atherosclerosis
por: Alonso, Nuria, et al.
Publicado: (2012)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Incretin hormones and the satiation signal
por: Holst, J J
Publicado: (2013)

Novel extrapancreatic effects of incretin
por: Yamada, Yuichiro, et al.
Publicado: (2016)

Incretins in patients with rheumatoid arthritis
por: Tejera-Segura, Beatriz, et al.
Publicado: (2017)

The Origin and Understanding of the Incretin Concept
por: Rehfeld, Jens F.
Publicado: (2018)

The Impact of Incretin-Based Medications on Lipid Metabolism
por: Yaribeygi, Habib, et al.
Publicado: (2021)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review
por: Kakouri, Agni, et al.
Publicado: (2021)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents
por: Ryan, Paul M., et al.
Publicado: (2017)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Incretin Therapy and Islet Pathology: A Time for Caution
por: Kahn, Steven E.
Publicado: (2013)

Dipeptidylpeptidase-IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats
por: Tarantola, E., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dvqfjqrjaac7vmhs5ukrg1f99e